CEQUENT PHARMACEUTICALS
An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases – from inflammatory diseases to cancer – based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deac... tivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006. In July 2010, Cequent Pharmaceuticals was acquired by Marina Biotech, Inc (formerly MDRNA, Inc) for $46M.
CEQUENT PHARMACEUTICALS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2006-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.cequentpharma.com
Total Employee:
11+
Status:
Active
Contact:
617-995-7940
Email Addresses:
[email protected]
Total Funding:
12.4 M USD
Technology used in webpage:
SPF Domain Not Resolving OVH
Similar Organizations
Vigeo Therapeutics
Vigeo Therapeutics is a biopharmaceutical company developing novel therapeutic agents intended to treat advanced malignant tumors.
Current Employees Featured
Founder
Investors List
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Cequent Pharmaceuticals
Nexus Medical Partners
Nexus Medical Partners investment in Series A - Cequent Pharmaceuticals
Ampersand Capital Partners
Ampersand Capital Partners investment in Series A - Cequent Pharmaceuticals
Pappas Ventures
Pappas Ventures investment in Series A - Cequent Pharmaceuticals
Official Site Inspections
http://www.cequentpharma.com
- Host name: ip79.ip-144-217-233.net
- IP address: 144.217.233.79
- Location: Beauharnois Canada
- Latitude: 45.3161
- Longitude: -73.8736
- Timezone: America/Toronto
- Postal: J6N
More informations about "Cequent Pharmaceuticals"
Cequent Pharmaceuticals - Prevent and Treat a Wide Range of …
An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases from inflammatory diseases …See details»
Company | Cequent Pharma
About Cequent Pharmaceuticals, Inc. An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human …See details»
Cequent Pharmaceuticals - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 617-995-7940 An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to …See details»
Cequent Pharmaceuticals Company Profile | Management and
Cequent Pharmaceuticals Profile and History . Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human disorders -- from inflammatory …See details»
Management Team - Cequent Pharma
Peter D. Parker President and CEO. Mr. Parker is President and CEO of Cequent Pharmaceuticals, Inc. Prior to joining Cequent, Mr. Parker was a General Partner at …See details»
Cequent Pharmaceuticals - PitchBook
Cequent Pharmaceuticals General Information Description. Developer of RNAi-based therapies based in Cambridge, Massachusetts. The company focuses on biopharmaceutical products …See details»
Cequent Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical ...
Explore Cequent Pharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»
Cequent Pharmaceuticals - Products, Competitors, Financials, …
Headquarters Location. One Kendall Square Building 700 First Floor. Cambridge, Massachusetts, 02139, United States. 617-995-7940See details»
Cequent Pharmaceuticals-动脉网 - vbdata.cn
Cequent Pharmaceuticals作为一家早期的生物制药公司，Cequent正在开发新型疗法，以预防和治疗各种人类疾病。从炎症性疾病到癌症。Cequent的第一批产品目前处于临床前开发阶段，是 …See details»
Coupa e-Procurement Software Goes Live at Cequent …
Aug 21, 2007 Cequent’s first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. A privately held company …See details»
Board of Directors - Cequent Pharma
Joining Peter D. Parker on the Cequent Pharmaceuticals, Inc. Board of Directors are: Chiang J. Li, M.D. Founder, Director and Chairman of Scientific Advisory BoardSee details»
Cequent Pharmaceuticals, Inc. Meets Novartis Corporation Option …
Sep 16, 2008 Cequent Pharmaceuticals, Inc. Meets Novartis Corporation (NVS) Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo …See details»
Cequent Pharmaceuticals - Pappas Capital
Cequent, which was acquired by Marina Biotech in 2010, developed new, clinically compatible therapies based on RNA interference (RNAi) therapies.See details»
Cequent Pharmaceuticals Asset Profile | Preqin
Www.cequentpharma.com Verticals HealthTech Company Stage Acquired Total Amount Raised Subscriber access only Time to go Pro Get Preqin Pro for unrestricted access to 600,000+ …See details»
Our Partners | Cequent Pharma
The Novartis Institutes for BioMedical Research (NIBR) is Novartis global research organization. Informed by clinical insights from their translational medicine team, NIBR uses modern science …See details»
Cequent Pharmaceuticals, Inc. Completes $9 Million Series A
CAMBRIDGE, Mass., June 18 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human …See details»
Cequent Pharmaceuticals, Inc. Names Ted Hibben Chief ... - BioSpace
CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human …See details»
Scientific Team - Cequent Pharma
Johannes Fruehauf, M.D. Vice President, Research Dr. Fruehauf is VP, Research at Cequent Pharmaceuticals, Inc. and co-inventor of transkingdom RNAi (tkRNAi).See details»
Welcome to Medicant Pharma
Medicant Pharma specializes in strategic partnerships with a select group of FDA compliant Active Pharmaceutical Ingredient manufacturer’s worldwide, unique Finished Dosage …See details»
Research and Development Overview - Cequent Pharma
The recent discovery of RNAi has created the opportunity to develop an entirely new class of drugs, which work by silencing individual disease genes. Despite the promise, however, a …See details»